Literature DB >> 3134150

In vivo immunopotentiating activity of thymopentin in aging humans: modulation of IL-2 receptor expression.

W Barcellini1, P L Meroni, M O Borghi, D Frasca, R Perego, G Doria, C Zanussi.   

Abstract

The effect of thymopentin treatment was investigated in immunocompromised elderly subjects. Thymopentin was able to increase IL-2 production and IL-2 receptor expression, as assessed on PHA-activated blasts by percentage of Tac-positive cells and response to exogenous IL-2. After treatment, an increased precursor frequency, estimated by limiting dilution analysis, of PHA-responding lymphocytes was observed in two out of six subjects tested. In vitro experiments with thymopentin show that the drug was able to enhance blastogenesis by PHA of elderly lymphocytes but not of adult cells. These results indicate that (a) the increased IL-2 synthesis/IL-2 receptor expression may be the crucial mechanism of the immunopotentiating activity of the drug in elderly subjects and (b) an increased intrinsic T-cell responsiveness seems to be responsible for this immunopotentiating activity, although an increase in the size of the responsive T-cell pool could not be excluded.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3134150     DOI: 10.1016/0090-1229(88)90078-5

Source DB:  PubMed          Journal:  Clin Immunol Immunopathol        ISSN: 0090-1229


  2 in total

1.  Thymopentin reduces the susceptibility of aged mice to cutaneous leishmaniasis by modulating CD4 T-cell subsets.

Authors:  E Cillari; S Milano; M Dieli; F Arcoleo; R Perego; F Leoni; G Gromo; A Severn; F Y Liew
Journal:  Immunology       Date:  1992-07       Impact factor: 7.397

Review 2.  Thymopentin and splenopentin as immunomodulators. Current status.

Authors:  V K Singh; S Biswas; K B Mathur; W Haq; S K Garg; S S Agarwal
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.